Search
Search Results
##search.searchResults.foundPlural##
-
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1351PDF: 718HTML: 191 -
INCREASE IN CANDIDA PARAPSILOSIS CANDIDEMIA IN CANCER PATIENTS
1678PDF: 1041HTML: 226 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3497PDF: 834HTML: 6694 -
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY. ITP and COVID19 infection and vaccination
1253PDF: 771HTML: 294 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1321PDF: 1270HTML: 78 -
-
ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS
2736PDF: 899HTML: 7299 -
INFECTIONS AND FOLLICULAR LYMPHOMA: IS THERE A LINK?
3137PDF: 973HTML: 1987 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
3951PDF: 1895HTML: 5191Table 1: 165 -
THE ROLE OF THE CAROTID DOPPLER EXAMINATION IN THE EVALUATION OF ATHEROSCLEROTIC CHANGES IN BETA THALASSEMIA PATIENTS
2080PDF: 877HTML: 2987Untitled: 180 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3956PDF: 1010HTML: 3555Untitled: 163Cneo. Fig.1: 97Untitled: 89Untitled: 110Untitled: 110 -
FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia
539PDF: 177Html: 24 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4705PDF: 1707HTML: 2686Untitled: 190 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1869PDF: 703HTML: 677 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1289HTML: 363PDF: 789 -
MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA Guest Editor: Giancarlo Costaman
3053PDF: 1562HTML: 390 -
WHAT UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA TAUGHT US ABOUT TRANSPLANT IMMUNOGENETICS.
3090PDF: 1099HTML: 1453Untitled: 159Untitled: 147Untitled: 147 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
554PDF: 271Suppl. Files: 102HTML: 95 -
EPIDEMIOLOGY OF MALARIA IN ENDEMIC AREAS
5147PDF: 2572HTML: 49542 -
-
PATHOGENESIS AND TREATMENT OF THROMBOHEMORRHAGIC DIATHESIS IN ACUTE PROMYELOCYTIC LEUKEMIA
1728PDF: 780HTML: 10204Figures 1,2,3: 152 -
FACTORS PREDICTING MORBIDITY IN PATIENTS WITH DENGUE FEVER IN A TERTIARY CARE HOSPITAL
2350HTML: 9376DOCX: 974Tables Dengue: 190 -
CEREBRAL VENOUS THROMBOSIS IN THE MEDITERRANEAN AREA IN CHILDREN
2463PDF: 922HTML: 2214 -
T-LYMPHOCYTES EXPRESSION OF TOLL-LIKE RECEPTORS 2 AND 4 IN ACUTE MYELOID LEUKEMIA PATIENTS WITH INVASIVE FUNGAL INFECTIONS Toll-like receptors 2 and 4 in Acute Myeloid Leukemia Patients with Invasive Fungal Infections
1691PDF: 655HTML: 312 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1244PDF: 981HTML: 108 -
-
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
1944PDF: 574Suppl. Files: 267HTML: 150 -
DEMOGRAPHICAL, VIRO-IMMUNOLOGICAL, CLINICAL AND THERAPEUTICAL CHARACTERISTICS OF HIV INFECTED PATIENTS IN A “EPIDEMIOLOGICALLY UNEXPLORED” REGION OF ITALY (CALABRIA REGION): THE CALABRHIV COHORT.
1553PDF: 761HTML: 1219Figure 1: 144Figure 2: 166Figure 3: 163







